Jane S. Ricciuti, RPh, MS

Disclosures

February 19, 2003

In This Article

Introduction

The US Food and Drug Administration (FDA) announced on January 31, 2003, a new initiative titled "Improving Innovation in Medical Technology: Beyond 2002." The FDA is proposing to establish new regulatory standards and processes to bring to market quicker and less costly new and emerging drugs, biologics, devices, and veterinary medicines. The proposal includes:

  • Reducing the delays and excess product development costs by avoiding multiple cycles of FDA review when possible, through early communication and other steps to improve the quality of new product applications.

  • Improving the quality and efficiency of the review process, by adopting a quality systems approach to medical product reviews.

  • Facilitating new product development, by providing clearer up-to-date guidance for particular diseases and for emerging technologies.

To highlight the need for a change in the regulatory processes, the FDA illustrated that the number of total products approved in 2002 had increased at the same time that there were fewer marketing applications and longer total approval times in some significant product areas.

The decrease in new molecular entities is demonstrated in this month's FDA Approvals column, where there are several significant supplemental approvals but only 1 New Drug Application (NDA) and 1 new Biologics License Application (BLA). The NDA for Xanax XR was approved by the FDA for the treatment of panic disorder. The BLA for Amevive (alefacept) injection was approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis. Amevive is an immunosuppressive dimeric fusion protein.

This month's column reviews FDA new product approvals and labeling changes for:

Antidepressants

  • Prozac (fluoxetine HCl) capsules

Antilipemic Agents

  • Lopid (gemfibrozil) tablets

Antihypertensive Agents

  • Atacand (candesartan cilexetil) tablets

  • Diovan HCT (valsartan/hydrochlorothiazide) tablets

Anti-infective Agents

  • Cancidas (caspofungin acetate) injection

  • Zyvox (linezolid) tablets and injection

Antineoplastic Agents

  • Busulfex (busulfan) injection

Cardiovascular Agents

  • Imdur (isosorbide mononitrate) extended-release tablets

  • Tenormin (atenolol) tablets

Central Nervous System Agents

  • Xanax XR (alprazolam) extended-release tablets

Dermatologic Agents

  • Amevive (alefacept) injection

Estrogens

  • Premarin (conjugated estrogens) tablets

  • Prempro (conjugated estrogens/medroxyprogesterone acetate) tablets

Immunosuppressive Agents

  • Rapamune (sirolimus) oral solution & tablets

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....